Nov 20, 2025 12:30 PM Eastern Standard Time "Insulet's clear leadership in diabetes care is supported by a strong balance sheet, operational scale, and a robust innovation pipeline that position us to deliver continued top-tier growth,†said Flavia Pease, Executive Vice President and Chief Financial Officer. "Our consistent cash-flow generation provides the flexibility to invest in innovation and scale, sustaining our momentum and creating long-term value for our stakeholders.†Insulet Outlines Long-Term St ...

Insulet (NasdaqGS:PODD) 2025 Investor Day November 20, 2025 09:00 AM ET Company ParticipantsCarolyn Sleeth - Head of US BusinessDavid Roman - Managing DirectorNone - Unknown Speaker 9None - Unknown Speaker 3None - Unknown Speaker 7None - Unknown Speaker 11Eric Benjamin - COOClaire Trachtman - VP of Investor RelationsNone - Unknown Speaker 4None - Unknown Speaker 5Manoj Raghunandanan - Chief Growth OfficerTrang Ly - Chief Medical OfficerNone - Unknown Speaker 8None - Unknown Speaker 6None - Unknown Speaker 2 ...

Core Insights - Insulet Corporation (PODD) reported a strong performance in Q3 2025, with adjusted earnings per share (EPS) of $1.24, reflecting a year-over-year increase of 37.8% and surpassing the Zacks Consensus Estimate by 9.73% [1] - Total revenues reached $706.3 million, exceeding the Zacks Consensus Estimate by 4.42% and showing a year-over-year growth of 29.9% [2] - The company raised its revenue growth outlook for 2025, now expecting a constant exchange rate (CER) growth of 28%-29% [7] Q3 Financial Performance - Adjusted EPS was $1.24, up 37.8% from the previous year, with GAAP EPS also at $1.24, marking a 14.8% increase [1] - Revenues totaled $706.3 million, a 29.9% increase year over year, with CER growth at 28.2%, surpassing the company's guidance range of 22%-25% [2] - Gross profit was $510.1 million, up 35.3% year over year, with a gross margin of 72.2%, expanding by 289 basis points [4] Segment Performance - Total Omnipod revenues were $699.2 million, reflecting a 31% year-over-year increase [3] - International Omnipod revenues rose 46.5% to $202.1 million, while U.S. Omnipod revenues grew 25.6% to $497.1 million [3] - The Drug Delivery business reported revenues of $7.1 million, down 31.4% year over year [3] Margin and Operating Performance - Operating profit for the quarter was $117.7 million, up 33.6% from the previous year, with an operating margin of 16.7%, expanding by 47 basis points [5] - Selling, general, and administrative expenses increased by 34.6% to $315.2 million, while research and development expenses rose by 40.6% to $77.2 million [4] Cash Position - Insulet ended Q3 2025 with cash and cash equivalents of $757.4 million, down from $1.12 billion at the end of Q2 [6] - Cumulative net cash provided by operating activities was $386 million, compared to $282.7 million in the same period last year [6] Future Outlook - For 2025, Insulet expects CER revenue growth of 28%-29% and total Omnipod revenue growth of 29%-30% [7] - The company projects Q4 revenue growth of 25%-28%, with total Omnipod revenues anticipated to grow 27%-30% [8] - The Zacks Consensus Estimate for 2025 revenues stands at $2.69 billion, with Q4 revenue consensus at $767.7 million [8] Market Developments - Insulet announced a partnership with Pantone to launch Omnipod Mango and secured reimbursement for Omnipod 5 with various CGM sensors in Norway [10] - The company has shown strong retention and growth in new Pod users, particularly in the Type 2 diabetes segment [9]

Core Insights - Insulet reported earnings of $1.24 per share on $706.3 million in third-quarter sales, exceeding analyst expectations of $1.14 per share and $678.4 million in sales [1][2] - The company's Omnipod insulin pump sales grew significantly, with a 25.6% increase in the U.S. and a 46.5% increase internationally [1] - For the year, Insulet has guided revenue growth to 28% to 29%, an increase from the previous forecast of 24% to 27% [2] Financial Performance - In the same period last year, Insulet earned 90 cents per share with $544 million in sales, indicating substantial year-over-year growth [2] - Analysts project earnings of $4.67 per share and total sales of $2.63 billion for the year [2] Stock Market Activity - Insulet's stock advanced 4% to $327 in premarket trading, with a cup-with-handle base forming and a buy point at $335.26 [3] - The stock may face downward pressure at its 50-day moving average [3]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

Core Viewpoint - Insulet Corporation (PODD) is an innovative medical device company focused on insulin delivery systems, with a market cap of $22.8 billion, and is set to announce its fiscal third-quarter earnings for 2025 on November 6 [1] Financial Performance - Analysts expect PODD to report a profit of $1.13 per share for the upcoming quarter, reflecting a 25.6% increase from $0.90 per share in the same quarter last year [2] - For the full fiscal year, EPS is projected to be $4.61, a 42.3% increase from $3.24 in fiscal 2024, with further growth expected to $5.76 in fiscal 2026, representing a 25% year-over-year rise [3] Stock Performance - PODD stock has outperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with PODD shares increasing by 37.7% during the same period [4] - The stock also outperformed the Health Care Select Sector SPDR Fund, which saw a 2.9% decline [4] Growth Drivers - The strong performance of PODD is attributed to significant growth in its Omnipod product line in both domestic and international markets [5] - Following the release of Q2 results, PODD shares surged 9.5% after reporting an adjusted EPS of $1.17, exceeding expectations of $0.93, with revenue reaching $649.1 million, surpassing forecasts of $615.5 million [5] Analyst Sentiment - The consensus among analysts is bullish, with a "Strong Buy" rating for PODD stock; 21 out of 25 analysts recommend a "Strong Buy," while two suggest a "Moderate Buy" and two a "Hold" [6] - The average analyst price target for PODD is $365.78, indicating a potential upside of 13.1% from current levels [6]

Core Insights - Insulet Corporation (PODD) is a leading medical device company focused on insulin delivery systems, with a market capitalization of $23.6 billion [1][2] - The company is recognized as a large-cap stock, emphasizing its significant influence in the medical devices industry and commitment to innovation through substantial R&D investments [2] - Insulet is expanding its global footprint by entering new markets and establishing distribution channels [2] Financial Performance - PODD's stock has experienced a decline of 7.3% from its 52-week high of $353.50, reached on September 9, while gaining 6.5% over the past three months, underperforming the S&P 500 Index's 10.5% gains [3] - Year-to-date, PODD shares have risen by 25.6% and 37.2% over the past 52 weeks, outperforming the S&P 500's YTD gains of 13.2% and 16.4% [4] - The stock has consistently traded above its 200-day moving average over the past year, indicating a bullish trend [4] Growth Drivers - The strong performance of PODD is attributed to significant growth in its Omnipod product line in both domestic and international markets [5] - Following the release of Q2 results, PODD shares surged by 9.5%, with an adjusted EPS of $1.17 surpassing Wall Street expectations of $0.93, and revenue of $649.1 million exceeding forecasts of $615.5 million [5] Analyst Sentiment - Wall Street analysts maintain a positive outlook on PODD, with a consensus "Strong Buy" rating from 24 analysts and a mean price target of $362.27, suggesting a potential upside of 10.5% from current levels [6]

Group 1 - ClearBridge Investments reported a strong rebound in U.S. equities during Q2 2025, with the S&P 500 Index returning 10.9% and the Russell 3000 Index advancing 11.0% due to improved risk sentiment following a pause in tariff implementation [1] - The ClearBridge Select Strategy outperformed its benchmark in Q2 2025, attributed to effective portfolio construction across various companies and sectors with distinct growth drivers [1] - Insulet Corporation (NASDAQ:PODD) was highlighted as a key stock, with a one-month return of -1.72% and a 52-week gain of 35.57%, closing at $322.22 per share on September 17, 2025, with a market capitalization of $22.682 billion [2] Group 2 - Insulet Corporation's health care exposure was noted as a standout despite overall sector struggles due to tariff fears and challenges in the Medicare Advantage market, benefiting from robust margin growth and FDA approval for Omnipod sales among type 2 diabetes patients [3] - Insulet Corporation's Q2 2025 revenue increased by 32% to $649 million, with 53 hedge fund portfolios holding its stock at the end of the quarter, up from 47 in the previous quarter [4]

Financial Data and Key Metrics Changes - The company has achieved 20% revenue growth for 10 consecutive years, with an acceleration to 70% gross profit this year, while expanding operating margins and maintaining cash flow positivity [11][66] - The company has nearly $1 billion on the balance sheet, providing opportunities for continued investment in growth [11] Business Line Data and Key Metrics Changes - The company is focusing on type one diabetes in the U.S. with low penetration and plans to leverage its first mover advantage in type two diabetes [5][17] - New customer starts for type two diabetes accelerated significantly, with a reported increase of approximately 43% year-over-year in the second quarter [25][17] Market Data and Key Metrics Changes - International markets have shown strong growth, with a 39% constant currency increase in the second quarter, driven by demand for Omnipod 5 [30][31] - The company has a significant opportunity in the type one diabetes market, with about 3.5 million people affected and only 20% penetration [31] Company Strategy and Development Direction - The company aims to evolve from being a disruptor to a market leader, focusing on innovation and geographic expansion [7][5] - Strategic priorities include enhancing market development, demand generation, and brand management to increase awareness of Omnipod [8][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the complexities of the type two diabetes market and the need to educate clinicians to reduce biases against insulin use [24][19] - The company plans to host an Investor Day on November 20th to discuss long-range plans and growth algorithms [9][36] Other Important Information - The company has invested over $1 billion in manufacturing excellence over the past decade, producing tens of millions of pods [4] - The company has established a strong pharmacy access model, covering 300 million lives in the U.S. and reaching 47,000 pharmacies [51][52] Q&A Session Summary Question: What are the strategic priorities over the next 12 to 24 months? - The company will continue to lead in type one diabetes while expanding into type two diabetes and investing in platform innovation [6] Question: How do you see the sustainability of strong new start growth? - The company is confident in its growth trajectory due to the vast market opportunity and low penetration rates [25] Question: What are the differences in utilization and attrition between type 2 and type 1? - Global retention remains stable, with type one showing stronger retention due to its life-threatening nature [22] Question: How does the company plan to sustain its first mover advantage? - The company has created durable competitive moats through technology, clinical evidence, and pharmacy access [50][51] Question: What is the company's response to potential CMS changes regarding Part D? - The company supports patient choice and has already innovated a pay-as-you-go model in pharmacy, which mitigates immediate risks [55]

Core Insights - Insulet Corporation (PODD) reported a significant increase in adjusted earnings per share (EPS) for Q2 2025, reaching $1.17, which is a 112.7% increase year-over-year and surpassing the Zacks Consensus Estimate by 25.81% [1] - The company's total revenues for Q2 2025 were $649.1 million, exceeding the Zacks Consensus Estimate by 5.46% and reflecting a 33% year-over-year growth [2] Revenue Performance - Total Omnipod revenues amounted to $639 million, marking a 33% increase year-over-year, with international revenues at $185.8 million growing 45% [3] - U.S. Omnipod revenues increased by 28.7% year-over-year to $453.2 million, while Drug Delivery business revenues rose 25.9% to $10.2 million [3] Margin Analysis - Gross profit for the quarter was $452.2 million, a 36.7% increase from the previous year, with a gross margin of 69.7%, expanding by 193 basis points [4] - Operating profit reached $121.1 million, up 122.2% year-over-year, with an operating margin of 18.7%, expanding by 750 basis points [5] Cash Position - At the end of Q2 2025, Insulet had cash and cash equivalents of $1.12 billion, down from $1.28 billion at the end of Q1 [6] - Cumulative net cash provided by operating activities was $260.3 million by the end of Q2 [6] Future Guidance - For 2025, Insulet expects constant exchange rate (CER) revenue growth of 24%-27%, up from the previous guidance of 19%-22% [7] - Total Omnipod revenue growth is projected at 25%-28%, while Drug Delivery revenues are expected to decline by 30%-25% [7] - For Q3, revenue growth is anticipated at 22%-25%, with total Omnipod revenues expected to grow 24%-27% [8] Overall Performance - Insulet's Q2 results indicate strong performance with both earnings and revenues exceeding estimates, driven by new customer acquisitions in the U.S. and internationally [10] - The company has experienced robust growth in key markets, particularly in the U.K., Germany, and France, contributing to its tenth consecutive year of over 20% growth on a constant-currency basis [11]